Half-year report · Q2
9627.TEDINET S100UY0P
Period2024-05-01 → 2024-10-31
Filed2024-12-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥214.9bn | 2024-05-01 → 2024-10-31 | Cons. | Net sales |
| Revenue | ¥399.8bn | 2023-05-01 → 2024-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥193.7bn | 2023-05-01 → 2023-10-31 | Cons. | Net sales |
| Operating income | ¥5.9bn | 2024-05-01 → 2024-10-31 | Cons. | Operating income |
| Operating income | ¥8.7bn | 2023-05-01 → 2023-10-31 | Cons. | Operating income |
| Ordinary income | ¥6.3bn | 2024-05-01 → 2024-10-31 | Cons. | Ordinary income |
| Ordinary income | ¥21.4bn | 2023-05-01 → 2024-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.3bn | 2023-05-01 → 2023-10-31 | Cons. | Ordinary income |
| Profit before tax | ¥6.7bn | 2024-05-01 → 2024-10-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.4bn | 2023-05-01 → 2023-10-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.4bn | 2023-05-01 → 2024-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.3bn | 2023-05-01 → 2023-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss |
| Net income | ¥5.2bn | 2023-05-01 → 2023-10-31 | Cons. | Profit loss |
| Total assets | ¥296.0bn | at 2024-10-31 | Cons. | Assets |
| Total assets | ¥249.4bn | at 2024-04-30 | Cons. | Assets |
| Total assets | ¥242.9bn | at 2023-10-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥159.9bn | at 2024-10-31 | Cons. | Liabilities |
| Total liabilities | ¥114.0bn | at 2024-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥136.1bn | at 2024-10-31 | Cons. | Net assets |
| Net assets / equity | ¥135.4bn | at 2024-04-30 | Cons. | Net assets |
| Net assets / equity | ¥129.8bn | at 2023-10-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.2bn | at 2024-10-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥48.6bn | at 2024-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.2bn | at 2024-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥48.4bn | at 2024-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥50.3bn | at 2023-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.2bn | at 2023-04-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.7bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.0bn | 2023-05-01 → 2024-04-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.1bn | 2023-05-01 → 2023-10-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥54.0bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.7bn | 2023-05-01 → 2024-04-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.8bn | 2023-05-01 → 2023-10-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥20.1bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.1bn | 2023-05-01 → 2024-04-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.2bn | 2023-05-01 → 2023-10-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥91.75 | 2024-05-01 → 2024-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥324.64 | 2023-05-01 → 2024-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.66 | 2023-05-01 → 2023-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 46.0% | at 2024-10-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.3% | at 2024-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.4% | at 2023-10-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-05-01 → 2024-10-31 | ¥5.6bn |
| Otherother segments | revenue external | 2024-05-01 → 2024-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| Otherother segments | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥5.0bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥9.6bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥1.7bn |
| —segment total | revenue | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue external | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| —segment total | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥11.3bn |
| Otherother segments | revenue | 2023-05-01 → 2023-10-31 | ¥5.7bn |
| Otherother segments | revenue external | 2023-05-01 → 2023-10-31 | ¥5.7bn |
| Otherother segments | revenue intersegment | 2023-05-01 → 2023-10-31 | ¥24m |
| Otherother segments | segment ordinary income | 2023-05-01 → 2023-10-31 | −¥49m |
| Reconciling Itemsreconciling | revenue | 2023-05-01 → 2023-10-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-05-01 → 2023-10-31 | −¥24m |
| Reconciling Itemsreconciling | segment ordinary income | 2023-05-01 → 2023-10-31 | −¥4.4bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2023-05-01 → 2023-10-31 | ¥173.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2023-05-01 → 2023-10-31 | ¥173.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2023-05-01 → 2023-10-31 | ¥12.5bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2023-05-01 → 2023-10-31 | ¥14.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2023-05-01 → 2023-10-31 | ¥14.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2023-05-01 → 2023-10-31 | ¥1.3bn |
| —segment total | revenue | 2023-05-01 → 2023-10-31 | ¥193.8bn |
| —segment total | revenue external | 2023-05-01 → 2023-10-31 | ¥193.7bn |
| —segment total | revenue intersegment | 2023-05-01 → 2023-10-31 | ¥24m |
| —segment total | segment ordinary income | 2023-05-01 → 2023-10-31 | ¥13.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 577
| Item | Context | Value | Unit |
|---|---|---|---|
| Directors compensations sga | Prior1YTDDuration | 228000000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 242000000 | JPY |
| Salaries allowances and bonuses sga | Prior1YTDDuration | 4010000000 | JPY |
| Salaries allowances and bonuses sga | CurrentYTDDuration | 5283000000 | JPY |
| Legal and employee benefits expenses sga | Prior1YTDDuration | 1465000000 | JPY |
| Legal and employee benefits expenses sga | CurrentYTDDuration | 1612000000 | JPY |
| Correspondence and transportation expenses sga | Prior1YTDDuration | 689000000 | JPY |
| Correspondence and transportation expenses sga | CurrentYTDDuration | 678000000 | JPY |
| Rents sga | Prior1YTDDuration | 2632000000 | JPY |
| Rents sga | CurrentYTDDuration | 3392000000 | JPY |
| Depreciation sga | Prior1YTDDuration | 808000000 | JPY |
| Depreciation sga | CurrentYTDDuration | 1247000000 | JPY |
| Amortization of goodwill sga | Prior1YTDDuration | 2156000000 | JPY |
| Amortization of goodwill sga | CurrentYTDDuration | 2573000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember | 173234000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 14832000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 5660000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 193727000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 193727000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 24000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 24000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -24000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember | 173234000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 14832000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 5685000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 193752000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -24000000 | JPY |
| Net sales | Prior1YTDDuration | 193727000000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember | 12492000000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 1318000000 | JPY |
| Ordinary income | Prior1YTDDuration_OtherReportableSegmentsMember | -49000000 | JPY |
| Ordinary income | Prior1YTDDuration_ReportableSegmentsMember | 13761000000 | JPY |
| Ordinary income | Prior1YTDDuration_ReconcilingItemsMember | -4422000000 | JPY |
| Ordinary income | Prior1YTDDuration | 9338000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember | 186439000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 22885000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 5535000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 214860000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 214860000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | 24000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 24000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -24000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |